Mobile CARE-App to Promote Coping for Caregivers of Patients Receiving Stem Cell Transplant

Last updated: November 16, 2025
Sponsor: Massachusetts General Hospital
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Blood Cancer

Neoplasms

Hematologic Neoplasms

Treatment

CARE Application

Usual Care

Clinical Study ID

NCT05709912
22-634
  • Ages > 18
  • All Genders

Study Summary

The goal of this research study is to determine whether a self-administered, psychosocial mobile application (CARE app) is effective at improving the quality of life and experience of caregivers of patients receiving hematopoietic stem cell transplantation (HCT).

Eligibility Criteria

Inclusion

Caregiver Inclusion Criteria:

  • Adult caregivers (>18 years) who is a relative or friend who live with the patientor is a designated caregiver as indicated during the transplant process.

  • Caregiver of a patient receiving allogeneic or autologous HCT for the treatment ofcancer

  • Ability to comprehend and speak English as the CARE app is only available in English

Exclusion

Patient Exclusion Criteria:

  • Caregivers of patients undergoing HCT for benign hematologic conditions

  • Caregivers with acute or unstable psychiatric or cognitive conditions which thetreating clinicians believes prohibits informed consent or compliance with studyprocedures

Study Design

Total Participants: 120
Treatment Group(s): 2
Primary Treatment: CARE Application
Phase:
Study Start date:
July 01, 2023
Estimated Completion Date:
December 01, 2026

Study Description

This is a randomized clinical trial to determine whether a psychosocial mobile application (CARE app) is effective at improving the quality of life and experience of caregivers of patients receiving hematopoietic stem cell transplantation (HCT). The CARE app was developed with the goal of addressing the needs of caregivers of HCT recipients.

Participants will be randomized into one of two study groups: CARE app plus Usual Care versus Usual Care.

Participation in this study is expected to last up to 100 days after HCT.

It is expected that about 120 people will take part in this research study.

The Leukemia and Lymphoma Society is supporting this research by providing funding.

Connect with a study center

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts 02215
    United States

    Site Not Available

  • Massachusetts General Hospital Cancer Center

    Boston 4930956, Massachusetts 6254926 02215
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.